PROQR THERAPEUTICS
ProQR Therapeutics is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa. The company's main product candidates are QR-010, QR-110, and QR-313. Its product pipeline includes QRX-704, QRX-504, QRX-421, QRX-323 etc.
PROQR THERAPEUTICS
Industry:
Biotechnology Genetics Health Care Therapeutics
Founded:
2012-01-01
Address:
Leiden, Zuid-Holland, The Netherlands
Country:
The Netherlands
Website Url:
http://www.proqr.com
Total Employee:
101+
Status:
Active
Contact:
0031-0854894932
Email Addresses:
[email protected]
Total Funding:
359.37 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Domain Not Resolving Euro Apple Mobile Web Clips Icon Google Font API Google Maps Mobile Non Scaleable Content Common Name Invalid ASP.NET
Similar Organizations
Cytoguide
Cytoguide is a biotech company that focuses on the development of combined drugs to treat monocyte- and macrophage-related diseases.
De Western Therapeutics Institute
De Western Therapeutics Institute is a biotechnology company that focuses on development of innovative new drags to serve patients worldwide
Medilink Therapeutics
Medilink Therapeutics is a biotech company focusing on next-generation antibody-drug conjugate Research & development.
Pathios Therapeutics
Pathios Therapeutics is a biotech company focused on the development of therapies for autoimmune diseases and cancer.
Regulus Therapeutics
Regulus Therapeutics is a clinical stage biopharmaceutical company focused on the development and discovery of microRNA therapeutics.
Ribon Therapeutics
Ribon Therapeutics is a biotechnology company focused on the development of therapeutics treatments targeting stress support pathways.
Tramontane Therapeutics
Tramontane Therapeutics is a gene therapy company creates solutions for common neurological and metabolic illnesses.
UMR 1283-8199
UMR 1283-8199 is a research laboratory that researches type 2 diabetes and related disorders.
Current Employees Featured
Founder
Stock Details
Investors List
Rett Syndrome Research Trust
Rett Syndrome Research Trust investment in Grant - ProQR Therapeutics
Eli Lilly
Eli Lilly investment in Post-IPO Equity - ProQR Therapeutics
Pontifax
Pontifax investment in Post-IPO Debt - ProQR Therapeutics
Sofinnova Partners
Sofinnova Partners investment in Series A - ProQR Therapeutics
Sofinnova Partners
Sofinnova Partners investment in Seed Round - ProQR Therapeutics
Official Site Inspections
http://www.proqr.com Semrush global rank: 2.73 M Semrush visits lastest month: 6.4 K
- Host name: 136-144-162-130.colo.transip.net
- IP address: 136.144.162.130
- Location: Eindhoven Netherlands
- Latitude: 51.4513
- Longitude: 5.4009
- Timezone: Europe/Amsterdam
- Postal: 5657
More informations about "ProQR Therapeutics"
ProQR leadership – An experienced team of healthcare …
ProQR's leadership is a strong team with proven track record. Find out who is on our management team, board of directors and scientific advisory board. ... Beam Therapeutics, Kymera Therapeutics, and the Biotechnology Industry …See details»
ProQR - Wikipedia
ProQR was founded in 2012 by chief executive officer (CEO) Daniel A. de Boer and co-founders Henri Termeer, Dinko Valerio and Gerard Platenburg. The initial pipeline of the company was to develop small-molecule drugs or gene therapy that would treat cystic fibrosis (CF). Positive proof of concept (PoC) was achieved in 2016 with the clinical trial of the molecule QR-010 targeting the gene coding for cystic fibrosis transmembrane conductance regulatorSee details»
Investors & Media | ProQR Therapeutics
ProQR is pioneering a next-generation RNA technology called Axiomer®, which uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression …See details»
ProQR Therapeutics - LinkedIn
ProQR Therapeutics | 13,958 followers on LinkedIn. ... Let's continue to learn from one another, challenge our assumptions, and build a more equitable future, both within our organization and beyond.See details»
ProQR Therapeutics - Crunchbase Company Profile
Organization. ProQR Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. ProQR Therapeutics is a biotech company focused on developments of drugs …See details»
Director, RNA Biology | Leiden Bio Science Park - lbsp.nl
At ProQR we want to create an inclusive culture where everyone can be valued for who they are and in which individual differences and the contributions in all forms are recognized and …See details»
Lilly and ProQR to Expand RNA Editing Collaboration
Dec 22, 2022 ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA therapies. ProQR is pioneering a next-generation RNA technology called …See details»
ProQR Therapeutics Company Profile - Office Locations ... - Craft
Sep 4, 2024 ProQR Therapeutics has 3 employees across 2 locations and €6.51 m in annual revenue in FY 2023. See insights on ProQR Therapeutics including office locations, …See details»
ProQR Therapeutics - VentureRadar
We are ProQR, a company on a mission to create new medicines for patients in need. We focus on a group of diseases called rare diseases, with a very high need for new medicines. Out of …See details»
ProQR Therapeutics N.V. (PRQR) Company Profile & Overview
Nov 15, 2024 ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company’s products pipeline includes …See details»
Pipeline | ProQR Therapeutics
ProQR is pioneering a next-generation RNA technology called Axiomer™, ... World Health Organization. Discovery Disc. Non-clinical Non-clin. Clinical Clin. AX-2402 Disease Rare …See details»
ProQR Announces Third Quarter 2023 Operating and Financial
Nov 7, 2023 ProQR Therapeutics N.V. Investor contact: Sarah Kiely ProQR Therapeutics N.V. T: +1 617 599 6228 [email protected] or Hans Vitzthum LifeSci Advisors T: +1 617 430 7578 …See details»
ProQR Therapeutics N.V. (PRQR) - Yahoo Finance Canada
ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for …See details»
Lilly and ProQR to Expand RNA Editing Collaboration - PR Newswire
Dec 22, 2022 Forward Looking Statements for ProQR This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking …See details»
ProQR Announces First Patients Dosed in Phase 2/3 Pivotal
Dec 16, 2021 ProQR Therapeutics N.V. Investor Contact: Sarah Kiely ProQR Therapeutics N.V. T: +1 617 599 6228 [email protected] or Hans Vitzthum LifeSci Advisors T: +1 617 430 7578 …See details»
Lilly and ProQR to Expand RNA Editing Collaboration
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about the benefits of a collaboration between Lilly …See details»
ProQR and Rett Syndrome Research Trust Join Forces with …
Jan 5, 2024 ProQR Therapeutics N.V. Investor contact: Sarah Kiely ProQR Therapeutics N.V. T: +1 617 599 6228 [email protected] or Peter Kelleher LifeSci Advisors T: +1 617 430 7579 …See details»
Today marks an expansion of the ProQR and Lilly partnership
Dec 22, 2022 The collaboration, originally announced in September 2021, applied ProQR’s proprietary Axiomer® RNA editing platform to target disorders of the liver and nervous system. …See details»
ProQR Announces Axiomer® RNA Editing Licensing and Research ...
Companies will collaborate to develop editing oligonucleotides directed to up to five targets using ProQR’s proprietary Axiomer ® RNA editing platform; ProQR to receive $50 million consisting …See details»